Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10588914 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9956231 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US10064875 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9855334 | PRIMUS PHARMS | Topical compositions comprising a corticosteroid |
Mar, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 28, 2020 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older; Plaque psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.
Dosage: CREAM;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9655907 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9433630 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9877974 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US10179137 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9775851 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9439911 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) | |
US9364485 | PRIMUS PHARMS | Topical formulations comprising a steroid |
Aug, 2030
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Treatment of plaque psoriasis
Dosage: SPRAY;TOPICAL